Beclometasone hydrofluoroalkane intranasal - Teva

Drug Profile

Beclometasone hydrofluoroalkane intranasal - Teva

Alternative Names: BDP HFA Nasal Aerosol; Beclometasone HFA intranasal - Teva; Beclomethasone HFA intranasal - Teva; Beclomethasone hydrofluoroalkane intranasal - Teva; Qnasl; Qnaze™

Latest Information Update: 06 Feb 2015

Price : $50

At a glance

  • Originator Teva Pharmaceutical Industries
  • Class Antiallergics; Antiasthmatics; Chlorinated steroids; Corticosteroids; Pregnadienetriols; Small molecules; Vascular disorder therapies
  • Mechanism of Action Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 19 Dec 2014 Registered for Seasonal allergic rhinitis and Perennial allergic rhinitis (In children) in USA (Intranasal)
  • 07 Nov 2014 Efficacy & adverse events data from a phase III trial in Perennial allergic rhinitis (in children aged 4-11 years) presented at the 71st Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI-2014)
  • 13 May 2014 Preregistration for Perennial allergic rhinitis and Seasonal allergic rhinitis (in children aged 4-11 years) in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top